Organic mitral regurgitation

Similar documents
Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Percutaneous Mitral Valve Repair

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017

What echo measurements are key prior to MitraClip?

MitraClip in the ICCU: Which Patient will Benefit?

ΔΙΑΔΕΡΜΙΚΗ ΑΝΤΙΜΕΤΩΠΙΣΗ ΔΟΜΙΚΩΝ ΠΑΘΗΣΕΩΝ: Ο ΡΟΛΟΣ ΤΗΣ ΑΠΕΙΚΟΝΙΣΗΣ ΣΤΟ ΑΙΜΟΔΥΝΑΜΙΚΟ ΕΡΓΑΣΤΗΡΙΟ ΣΤΗΝ ΤΟΠΟΘΕΤΗΣΗ MITRACLIP

Prognostic Impact of FMR

Catheter-based mitral valve repair MitraClip System

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC

MitraClip World Wide Commercial Experience

8/31/2016. Mitraclip in Matthew Johnson, MD

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid

CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ;

Who will Benefit from Percutaneous Management of Mitral Regurgitation? An Imaging Guide to Management

Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain

Current status: Percutaneous mitral valve therapy

Degenerative Mitral Regurgitation: Etiology and Natural History of Disease and Triggers for Intervention

Percutaneous Mitral Valve Repair

Percutaneous Repair for MR:

Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine

Σεμινάρια Ομάδων Εργασίας 2017 Ανεπάρκεια μιτροειδούς μυξωματώδους αιτιολογίας

Introducing the COAPT Trial

Use of MitraClip Beyond Everest Criteria

Primary Mitral Regurgitation

Routine MitraClip. Image Guidance Step by Step

Mitral Valve prolapse: What s new? Which indications of early surgery? Input of new 2017 ESC/EACTS guidelines. Christophe Tribouilloy Amiens, France

Management of TR in Patients Undergoing Mitral Interventions

JOINT MEETING 2 Tricuspid club Chairpersons: G. Athanassopoulos, A. Avgeropoulou, M. Khoury, G. Stavridis

MITRAL REGURGITATION ECHO PARAMETERS TOOL

Repair or Replacement

Mitral Valve Disease, When to Intervene

Simultaneous Double Clipping Delivery Guide Strategy for Treatment of Severe Coaptation Failure in Functional Mitral Regurgitation

Percutaneous mitral valve repair: current techniques and results

The Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines

Balloon mitral valvuloplasty

Επιδιόπθωζη μιηποειδικήρ ζςζκεςήρ ζε ππόπηωζη ή πήξη γλωσίνων. Βαζίλειορ Σασπεκίδηρ Επιμεληηήρ Β Καπδιολογίαρ Γ.Ν. Παπαγεωπγίος

Τελικά επιδιόρθωση, αντικατάσταση ή clip στην ισχαιμική ανεπάρκεια Μιτροειδούς; ΒΛΑΣΗΣ ΝΙΝΙΟΣ MD MRCP ΚΛΙΝΙΚΗ ΑΓΙΟΣ ΛΟΥΚΑΣ

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC

Case Report. Percutaneous Mitral Repair with MitraClip as an Adjunct Therapy of Heart Failure. Introduction. Case Report. Keywords

Bogdan A. Popescu. University of Medicine and Pharmacy Bucharest, Romania. EAE Course, Bucharest, April 2010

Echocardiographic Evaluation of Primary Mitral Regurgitation

Really Less-Invasive Trans-apical Beating Heart Mitral Valve Repair: Which Patients?

Understanding the guidelines for Interventions in MR. Ali AlMasood

Index. B B-type natriuretic peptide (BNP), 76

Treatment of Inter-MitraClip Regurgitation Due to Posterior Leaflet Cleft by Use of The Amplatzer Vascular Plug II device

Percutaneous Mitral Valve Repair. Transesophageal Echo Acquisition Guide

Aortic Regurgitation and Aortic Aneurysm - Epidemiology and Guidelines -

Ανεπάρκεια Τριγλώχινας Επιλογή Επεμβατικής Θεραπείας. Μ. Χρυσοχέρης Τμήμα Διαδερμικών Βαλβίδων ΔΘΚΑ ΥΓΕΙΑ

Chronic Primary Mitral Regurgitation

Valve Analysis and Pathoanatomy: THE MITRAL VALVE

Transthoracic Echocardiographic

Percutaneous Mitral Valve Therapies

Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT

Les valvulopathies en sourdine: la valve mitrale Quoi faire devant une régurgitation mitrale sévère asymptomatique de type dégénérative?

What is the Role of Surgical Repair in 2012

Transcatheter Echo Guided Mitral Valve Repair with NeoChord Implantation: Results from NeoChord Independent International Registry

Transcatheter Mitral & Tricuspid Therapies. Bernard J. Zovighian Corporate Vice President

Mitral regurgitation (MR) is the second most

Prosthesis-Patient Mismatch or Prosthetic Valve Stenosis?

Functional Mitral Regurgitation; therapeutic continuum overview. Michele Senni. Cardiologia 1 Scompenso e Trapianti di Cuore A.O. PAPA GIOVANNI XXIII

Valvular Intervention

MR echo case. N.Koutsogiannis Department of Cardiology University Hospital Of Patras

When Does 3D Echo Make A Difference?

Functional Mitral Regurgitation

10 ο ΣΥΝΕΔΡΙΟ ΕΠΕΜΒΑΤΙΚΗΣ ΚΑΡΔΙΟΛΟΓΙΑΣ ΚΑΙ ΗΛΕΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ Σεπτεμβρίου 2017 Electra Palace Θεσσαλονικη

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL

Outcomes of Mitral Valve Repair for Mitral Regurgitation Due to Degenerative Disease

Mitral Regurgitation

Echocardiographic evaluation of mitral stenosis

MITRAL STENOSIS: MANY FLAVORS Rheumatic and Calcification. Rheumatic Mitral Stenosis 76yo male

Imaging MV. Jeroen J. Bax Leiden University Medical Center The Netherlands Davos, feb 2015

Burden of Mitral Regurgitation (MR) in the US Why is This Important?

Advanced Evaluation of Left Ventricular Function in Degenerative MR. Dr Julien Magne, PhD University of Liege, CHU Sart Tilman, Liege, Belgium

GDMT for percutaneous mitral valve repair

Multi-imaging modality approach. Covadonga Fernández-Golfín Cardiac Imaging Unit. Cardiology Department. Ramón y Cajal Hospital.

The Key Questions in Mitral Valve Interventions. Where Are We in 2018?

Regurgitant Lesions. Bicol Hospital, Legazpi City, Philippines July Gregg S. Pressman MD, FACC, FASE Einstein Medical Center Philadelphia, USA

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

ICE: Echo Core Lab-CRF

When should we intervene surgically in pediatric patient with MR?

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan

Mitral regurgitation (MR) is the most common

Professor and Chief, Division of Cardiac Surgery Chief Medical Officer, Harpoon Medical. The Houston Aortic Symposium February 23-25, 2017

VALVULOPATIE: NUOVE SOLUZIONI.

Milind Desai Christine Jellis Teerapat Yingchoncharoen Editors. An Atlas of Mitral Valve Imaging

ECHO HAWAII. Role of Stress Echo in Valvular Heart Disease. Not only ischemia! Cardiomyopathy. Prosthetic Valve. Diastolic Dysfunction

Real-World Experience of MitraClip for Treatment of Severe Mitral Regurgitation

Euro Heart Survey New Programme Sentinel Registry Transcatheter Valve Treatment (TCVT) Carlo Di Mario, London, UK President EAPCI

Successful Percutaneous Closure of Mitral Bioprosthetic Paravalvular Leak Using Figulla ASD Occluder

Clinical Value of 3D Echo: Volumes and Valves

Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F.

Next Generation Therapies: Aortic, Mitral and Beyond

Role of real-time three-dimensional transesophageal echocardiography in mitral valve repair

Status Of The MitraClip: Trials (EVEREST II & COAPT) & FDA

Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας

ΓΙΩΡΓΟΣ ΜΑΚΑΒΟΣ, MD, PhD ΚΑΡΔΙΟΛΟΓΟΣ, ΕΠΙΜΕΛΗΤΗΣ Β Γ ΠΑΝΕΠΙΣΤΗΜΙΑΚΗ ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Γ.Ν.Ν.Θ.Α. ΣΩΤΗΡΙΑ

Revealing new insights. irotate electronic rotation and xplane adjustable biplane imaging. Ultrasound cardiology. irotate and xplane

Contemporary Management of Mitral Regurgitation Tailoring Treatment to The Patient Subset & Clinical Situation

Transcription:

The best in heart valve disease Organic mitral regurgitation Ewa Szymczyk Department of Cardiology Medical University of Lodz, Poland I have nothing to declare

Organic mitral regurgitation leaflet abnormality is the primary cause of MR degenerative disease -> most common in Europe Barlow disease fibroelastic degeneration Marfan disease Ehler s-danlos disease annular calcification rheumatic disease endocarditis development of surgical MV repair introduced in 1970 by Alain Carpentier has dramatically changed the prognosis and the management of severe MR

Mitral regurgitation current therapeutic options Medical management Effective in symptom management Ineffective in patients with underlying pathophysiology and progression of disease Surgical Repair or Replacement (standard of care) Effective (invasive) with associated morbidity Only ~20% of patients with significant MR undergo MV surgery (high surgical risk, co-pathologies) Need for an effective less invasive option!

Source: Abbott Vascular

MitraClip global experience Until 04.2011 3.135 pts treated with Mitraclip 80 hospitals in EU 40 clinical trial sites in US Study N EVEREST I 55 EVEREST II Roll-in 60 EVEREST II HRR 78 EVEREST II randomized 184 REALISM (continued access) 571 Commercial use (EU) 2187 Source: Abbott Vascular

MitraClip 4-mm-wide Co Cr device two arms opened/closed with the use of the delivery-system handle mitral leaflets grasped, and the device is closed to approximate the leaflets procedure under general anesthesia fluoroscopic and TEE guidance atrial transseptal puncture Feldman T et al. NEJM 2011;364:1395-406

Case selection important anatomical prerequisites for MitraClip sufficient leaflet tissue for mechanical coaptation resting mitral valve effective orifice area over 4 cm 2 (small reduction in valve area on the transformation to a double orifice) In cases of degenerative MR with flail segments the flail gap should be <10 mm the flail width <15 mm coaptation lenght should be 2mm Exclusion - rheumatic MR and calcified leaflets!!! Jilaihawi et al. J Zhejiang Univ-Sci B 2011

Commercial EU Implant Experience Source: Abbott Vascular

EVEREST II

EVEREST II Randomized Clinical Trial Study Design 279 Patients enrolled at 37 sites Significant MR (3+-4+) Specific Anatomical Criteria Randomized 2:1 MitraClip System n=184 Surgical Repair or Replacement n=95 Echocardiography Core Lab and Clinical Follow-Up: Baseline, 30 days, 6 months, 1 year, 18 months, and annually through 5 years Feldman T et al. NEJM 2011;364:1395-406

Feldman T et al. NEJM 2011;364:1395-406 EVEREST II MR etiology characteristic Cause of MR Percutaneous repair (N=184) Surgery (N=95) Functional 49 (27%) 26 (27%) Degenerative - with anterior of bileaflet fail or prolapse - with posterior flail or prolapse - with no flail and no prolapse 58 (32%) 25 (26%) 72 (39%) 42 (44%) 5 (3%) 2 (2%)

Feldman T et al. NEJM 2011;364:1395-406 EVEREST II - primary endpoints (safety & effectiveness) * freedom from death, MV surgery, 3+ MR

Feldman T et al. NEJM 2011;364:1395-406 EVEREST II secondary efficacy end points at 12 months improvement in comparison to baseline in both groups according to: NYHA functional class left ventricular size quality-of-life measures

EVEREST II RTC Mitraclip Arm MR reduction by etiology

EVEREST II RTC Mitraclip Arm LV function by etiology

EVEREST II RTC Mitraclip Arm NYHA class by etiology

EVEREST II - conclusions Percutaneous repair was associated with superior safety and similar improvements in clinical outcomes compared to conventional surgery, despite being less effective at reducing MR the first prospective randomized trial comparing a percutaneous mitral repair technique to conventional surgery MitraClip percutaneous repair is a safe and effective technique that will be particularly applicable to high surgical risk patients or younger patients seeking a less invasive approach Feldman T et al. NEJM 2011;364:1395-406

Comparison of 2D TEE (n=80) vs. 3D/2D TEE (n=57) for MitraClip Repair Combined imaging: resulted in greater confidence of interpretation of MV anatomy and MR jet origin (p<0.001), facilitated correct clip positioning resulted in shorter precedural time (241± 58 vs 201 ±68 min, p=0.035) Procedural success and final MR grade were similar Biner et al. J Am Soc Echocardiogr 2011;24:611-7

RT-3D-TEE for assessment of MV anatomy in pts with prolapse-related regurgitation 222 pts undergoing repair for prolapse-related MR aim of the study: evaluation the additional diagnostic value of RT-3D-TEE for surgical findings in comparison to other echo modalities La Canna et al. Am J Cardiol. 2011;107:1365-74.

Correlation between echocardiographic imaging and surgical site of prolapse Simple lesions Complex lesions surgically confirmed surgically non-confirmed La Canna et al. Am J Cardiol. 2011;107:1365-74.

Correlation between echocardiographic imaging and surgical site of prolapse 3 middle scallops of posterior leaflet split by complete clefts RT3D-TEE provided more accurate mapping of MV prolapse than 2D imaging and RT3D-TTE, adding quantitative recognition of dominant and secondary lesions and MV anatomy details. monolobe P2 separated by 2 clefts from lateral and medial scallops of posterior leaflet La Canna et al. Am J Cardiol. 2011;107:1365-74.

LA size is a potent predictor of mortality in MR due to flail leaflets Overall survival by LA diameter under conservative treatment 788 pts in sinus rhythym with organic MR due to flail leaflets LA diameter was independently associated with survival after diagnosis (HR 1.08 per 1mm increment) Rusinaru D et al. Circ Cardiovasc Imaging. 2011;4:473-481.

Left atrial size > 55mm as a potent predictor of mortality in mitral regurgitation due to flail leaflets Conservative treatment Medical and surgery treatment LA 55mm - lower 8-year overall survival (P<0.001) LA 55mm independently predicted overall (HR=3.67) and cardiac mortality (HR=3.74) under medical treatment Mitral surgery was associated with greater survival benefit in pts with LA 55 mm (vs LA 55 mm) (P=0.008) Rusinaru D et al. Circ Cardiovasc Imaging. 2011;4:473-481.

Prognostic value of BNP in asymptomatic organic MR study material & methods Optimal timing of surgery is crucial in MR to avoid excess mortality and morbidity! Role of BNP? 87 pts with asymptomatic severe organic MR LVEF > 60% LVESD < 26 mm/m2 SPAP < 50mmHg Serial BNP assessment www.sciencephoto.com Primary endpoint - development of symptoms or LV dysfunction Secondary endpoint FA, pulmonary hypertension Klaar et al. European Journal of Heart Failure 2011;13:163-169.

BNP as predictor of primary endpoint within 6-months following measurement Primary endpoint development of symptoms or LV dysfunction Klaar et al. European Journal of Heart Failure 2011;13:163-169.

BNP as predictor of primary endpoint within 6-months following measurement BNP independently predicts outcome in pts with asymptomatic MR and normal LV function (controversial indication for surgery) Low plasma BNP levels, with high NPV - helpful by identifying individuals at low risk Serial measurements of BNP or NT-proBNP may help to improve the timing of intervention in MR. Asymptomatic MR pts with normal LV function, low BNP levels, and SPAP<40 mmhg can be safely followed. Klaar et al. European Journal of Heart Failure 2011;13:163-169.

Pocket-sized echo for evaluation of mitral and tricuspid regurgitation Electronic miniaturization portable transthoracic echocardiography imaging devices (pocket-sized echo) Capability of color Doppler imaging Kono et al. J Am Coll Cardiol Img 2011

Pocket-sized echo for evaluation of mitral and tricuspid regurgitation measurements feasible in 100% pts excellent correlations in MR jet area, left atrial area, %MR between pocket and standard echo (r=0.89-0.96, p<0.001) very high sensitivity/specificity for detecting moderate and significant MR (both 96%) - same as for standard echo limitations: small display limited control features Conclusion pocket-sized TTE with color Doppler feature is feasible and accurate in the assessment of severity and etiology of MR and should enhance the widespread its use in clinical practice Kono et al. J Am Coll Cardiol Img 2011

Michalski et al. Echocardiography 2011, Nov 2 [Epub ahead of print]

2011 year Stone G, TCT 2011

Organic mitral regurgitation - summary percutaneus less-invasive therapeutic option for pts with organic MR MitraClip as a safe and effective technique (high surgical risk pts) RT3D-TEE provides more accurate mapping of MV anatomy details adds quantitative recognition of dominant and secondary lesions in MVP enhance the confidence of interpretation concerning catheter-clip system location (shorter MV repair time)

Organic mitral regurgitation - summary left atrial size > 55mm as a potent predictor of mortality in MR due to flail leaflets, mitral surgery was associated with greater survival benefit in this group asymptomatic MR pts with normal LV function, low BNP levels, and SPAP<40 mmhg can be safely followed pocket-sized TTE with color Doppler is feasible and accurate in the assessment of severity and etiology of MR (possible widespread its use in clinical pracice)

Guidelines on the management of VHD. Eur Heart J. 2007;28: 230 268

Guidelines on the management of VHD. Eur Heart J. 2007;28: 230 268

Guidelines on the management of VHD. Eur Heart J. 2007;28: 230 268

Guidelines on the management of VHD. Eur Heart J. 2007;28: 230 268